Linda Bingener
Research Subjects
Research Interests
Linda Bingener has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Just
Department of Human Medicine, General Practice I and Interprofessional Care, Institute of General Practice and Primary Care Witten/Herdecke University Witten Germany
1 shared publication - Klaus Weckbecker
Institute of General Practice and Family Medicine, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
1 shared publication - Markus Bleckwenn
Institut für Allgemeinmedizin, Universität Leipzig, Medizinische Fakultät, Philipp-Rosenthal-Straße 55, Haus W, 04103, Leipzig, Deutschland.
1 shared publication - Rieke Schnakenberg
Faculty of Medicine and Health Siences, Department of Health Services Research, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany
1 shared publication
Latest Publications
- Open Access
- 20 June 2018
- Published by Springer Nature in BMC Family Practice
- Vol. 19 (1) , 1-5
Risk of opioid misuse in chronic non-cancer pain in primary care patients - a cross sectional study
Efforts to improve treatment of pain using opioids have to adequately take into account their therapeutic shortcomings which involve addictiveness. While there are no signs of an “opioid epidemic” in Germany similar to that in the US, there is little data on the prevalence of prescription opioid misuse and addiction. Therefore, our objective was to screen primary care patients on long-term opioid therapy for signs of misuse of prescription opioids. We recruited 15 GPs practices and asked all patients on long-term opioid therapy (> 6 months) to fill out a questionnaire including the “Current Opioid Misuse Measure” (COMM®), a self-report questionnaire. Patients with a malignant disease were excluded. N = 91 patients participated in the study (response rate: 75.2%). A third (31.5%) showed a positive COMM® - Score which represents a high risk of aberrant drug behaviour. A positive COMM® - Score showed a statistically significant correlation with a lifetime diagnosis of depression and neck pain. While Germany does not face an “opioid eoidemic”, addictiveness of opioids should be considered when using them in chronic non-tumor pain. In our study population, almost every third patient was at risk and should therefore be followed up closely. Co-prevalence of depression is a significant issue and should always be screened for in patients with chronic pain, especially thus with aberrant drug behaviour.
- 20 June 2018
- Published by Springer Nature in BMC Family Practice
- Vol. 19 (1) , 1-5
Open AccessRisk of opioid misuse in chronic non-cancer pain in primary care patients - a cross sectional study
Efforts to improve treatment of pain using opioids have to adequately take into account their therapeutic shortcomings which involve addictiveness. While there are no signs of an “opioid epidemic” in Germany similar to that in the US, there is little data on the prevalence of prescription opioid misuse and addiction. Therefore, our objective was to screen primary care patients on long-term opioid therapy for signs of misuse of prescription opioids. We recruited 15 GPs practices and asked all patients on long-term opioid therapy (> 6 months) to fill out a questionnaire including the “Current Opioid Misuse Measure” (COMM®), a self-report questionnaire. Patients with a malignant disease were excluded. N = 91 patients participated in the study (response rate: 75.2%). A third (31.5%) showed a positive COMM® - Score which represents a high risk of aberrant drug behaviour. A positive COMM® - Score showed a statistically significant correlation with a lifetime diagnosis of depression and neck pain. While Germany does not face an “opioid eoidemic”, addictiveness of opioids should be considered when using them in chronic non-tumor pain. In our study population, almost every third patient was at risk and should therefore be followed up closely. Co-prevalence of depression is a significant issue and should always be screened for in patients with chronic pain, especially thus with aberrant drug behaviour.